0001062993-21-000396.txt : 20210115
0001062993-21-000396.hdr.sgml : 20210115
20210115161910
ACCESSION NUMBER: 0001062993-21-000396
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210113
FILED AS OF DATE: 20210115
DATE AS OF CHANGE: 20210115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Skvarka Jan
CENTRAL INDEX KEY: 0001838042
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36596
FILM NUMBER: 21532322
MAIL ADDRESS:
STREET 1: C/O TRILLIUM THERAPEUTICS INC.
STREET 2: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trillium Therapeutics Inc.
CENTRAL INDEX KEY: 0001616212
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
BUSINESS PHONE: (416) 595-0627
MAIL ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2021-01-13
0001616212
Trillium Therapeutics Inc.
TRIL
0001838042
Skvarka Jan
C/O TRILLIUM THERAPEUTICS INC.
2488 DUNWIN DRIVE
MISSISSAUGA
A6
L5L 1J9
ONTARIO, CANADA
1
1
0
0
President and CEO
Common Shares
2021-01-13
4
M
0
5419
0.4248
A
5419
D
Common Shares
2021-01-13
4
S
0
5419
15.0411
D
0
D
Common Shares
2021-01-14
4
M
0
19581
0.4275
A
19581
D
Common Shares
2021-01-14
4
S
0
19581
15.0288
D
0
D
Stock Option (Right to Buy)
0.4248
2021-01-13
4
M
0
5419
0
D
2029-09-25
Common Shares
5419
1269581
D
Stock Option (Right to Buy)
0.4275
2021-01-14
4
M
0
19581
0
D
2029-09-25
Common Shares
19581
1250000
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7867 USD.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7916 USD.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
/s/ James Parsons, Attorney-in-Fact
2021-01-15